Leerink Partners Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $45
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.
Leerink Partners analyst Daniel Clark initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $45.